Shares of Alignment Health (ALHC) fell 11.59% to $11.44 on Monday, September 15, after the company discussed its results and outlook at the 2026 Global Healthcare Conference. The stock closed the prior session at $12.94 and trades within a 52-week range of $10.36 to $25.12.
Management provided no change to its 2026 guidance and said its 2027 bid was submitted with conservative assumptions that reflect the current operating environment. Revenue for the trailing twelve months through Q2 2026 came in at $4.58 billion, up 37% year over year, with EBITDA of $87.4 million. The company has reached 300,000 members and $5 billion in cumulative revenue.
On the earnings side, Alignment Health disclosed that its current membership base carries approximately $880 million in embedded earnings power, compared with $640 million at the midpoint of its current-year guidance — implying roughly $240 million in additional profit potential as those members age into more mature cohorts. The company plans to invest another $10 million to $11 million in the second half of the year.
Cost headwinds remain concentrated in institutional acute care. CEO John Kao and CFO Jim Head pointed to higher hospital billing pressure — including disputes, appeals and lagging 2025 dates-of-service bills — as well as longer skilled nursing facility stays. Industry regulatory factors cited included the "One Great Beautiful Bill," the Two-Midnight Rule and increased use of artificial intelligence, all contributing to billing disputes and appeals.
Prior-year development included about $6 million of unfavorable adjustments, largely tied to the transition of the claims management system. The company noted that medical loss ratios in its cohort model typically begin near 93% and improve to roughly 82% by year five.
California continues to show strong economics and 24% growth, while newer-state markets are composed of about 80% year-one and year-two members. Analysts at Baird, led by Michael Ha, moderated the session alongside Harrison Zhou, head of investor relations.
Wall Street price targets for the stock range from $16 to $30. Alignment Health declined to comment on measure-level Star Ratings performance or cut-point visibility ahead of the mid-October disclosure, citing CMS regulatory sensitivity.
The company's PEG ratio stands at 0.38, and its financial health score was rated 3.21 out of 5.
